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Abstract
Using a lectin, Achatinin-H, having preferential specificity for glycoproteins with terminal 9-O-acetyl sialic acid derivatives
linked in a2-6 linkages to subterminal N-acetylgalactosamine, eight distinct disease-associated 9-O-acetylated
sialoglycoproteins was purified from erythrocytes of visceral leishmaniaisis (VL) patients (RBCVL). Analyses of tryptic
fragments by mass spectrometry led to the identification of two high-molecular weight 9-O-acetylated sialoglycoproteins as
human erythrocytic a- and b-spectrin. Total spectrin purified from erythrocytes of VL patients (spectrinVL) was reactive with
Achatinin-H. Interestingly, along with two high molecular weight bands corresponding to a- and b-spectrin another low
molecular weight 60 kDa band was observed. Total spectrin was also purified from normal human erythrocytes (spectrinN)
and insignificant binding with Achatinin-H was demonstrated. Additionally, this 60 kDa fragment was totally absent in
spectrinN. Although the presence of both N- and O-glycosylations was found both in spectrinN and spectrinVL, enhanced
sialylation was predominantly induced in spectrinVL. Sialic acids accounted for approximately 1.25 kDa mass of the 60 kDa
polypeptide. The demonstration of a few identified sialylated tryptic fragments of a- and b-spectrinVL confirmed the
presence of terminal sialic acids. Molecular modelling studies of spectrin suggest that a sugar moiety can fit into the
potential glycosylation sites. Interestingly, highly sialylated spectrinVL showed decreased binding with spectrin-depleted
inside-out membrane vesicles of normal erythrocytes compared to spectrinN suggesting functional abnormality. Taken
together this is the first report of glycosylated eythrocytic spectrin in normal erythrocytes and its enhanced sialylation in
RBCVL. The enhanced sialylation of this cytoskeleton protein is possibly related to the fragmentation of spectrinVL as
evidenced by the presence of an additional 60 kDa fragment, absent in spectrinN which possibly affects the biology of
RBCVL linked to both severe distortion of erythrocyte development and impairment of erythrocyte membrane integrity and
may provide an explanation for their sensitivity to hemolysis and anemia in VL patients.
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Introduction
The erythrocyte membrane is supported by a well-structured
cytoskeleton. This cytoskeleton comprises of a network of different
proteins maintaining the structural integrity and rigidity of the red
blood cell (RBC) and of the RBC membrane [1]. Spectrin is a
major cytoskeletal protein present as tetramers of a- and b-
subunits associated with other cytoskeletal proteins forming a
lattice that governs erythrocyte membrane properties. Alterations
of spectrin have been associated with several congenital anomalies
like hereditary hemolytic anemia and hereditary elliptocytosis
leading to cellular distortion [2]. Biochemical modifications of
spectrin, mainly glycation and oxidation, have been observed in
diabetes mellitus indicating erythrocyte membrane changes [3–4].
Therefore, the status of the cytoskeletal proteins in disease may be
affected by genetic abnormalities or metabolic or other stress
inducing changes in cytoskeletal protein structure.
Different levels and/or pattern of terminal sialic acid (SA) and
its O-acetylation of cell surface expressed sialoglycoconjugates have
occupied a pivotal position in inducing changes in different
diseases [5–8]. The presence of different derivatives of SA on
Leishmania donovani [9–13], different immune cells [14,15] and
RBC [16–18] of patients with visceral leishmaniasis (VL) (RBCVL)
and their role [19–26] have been demonstrated.
VL caused by the intracellular kinetoplastid protozoa L. donovani
accounts for an estimated 12 million infected humans with an
incidence of 0.5 million cases per year [27–28]. Approximately
50% of the world’s VL cases occur in the Indian subcontinent.
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associated with anemia [17–18]. However alteration of the RBC
membrane architecture as one of the causes leading to anemia
remains poorly understood.
We have detected the exclusive presence of eight distinct
disease-associated 9-O-acetylated sialoglycoproteins (9-O-AcSGPs)
on RBCVL [17], using the preferential specificity of a snail lectin,
Achatinin-H for glycoproteins with terminal 9-O-acetyl sialic acid
(9-O-AcSA) derivatives linked in a2-6 linkages to subterminal N-
acetylgalactosamine (GalNAc) [29]. Interestingly, normal erythro-
cytes (RBCN) are devoid of such 9-O-AcSGPs. Antibodies directed
against O-acetylated sialic acids have also been demonstrated in
VL [30,15]. Moreover enhanced pattern of altered sialylation
demonstrated a direct correlation with the degree of complement-
mediated hemolysis of RBCVL providing a plausible basis for
anemia associated with VL [18]. Taking into consideration the
involvement of 9-O-AcSGPs in VL erythrocyte pathology, we
report the presence, purification and identification of sialylation,
N- and O-glycosylation of two high molecular weight O-acetylated
sialoglycoproteins as human eythrocytic a and b-spectrin by
analysis of the tryptic fragments using matrix-assisted laser
desorption/ionization time-of-flight (MALDI-TOF)/post source
decay (PSD) mass spectrometry (MS). Purified of spectrinVL
showed the presence of an additional 60 kDa band which is
completely absent in spectrinN purified by the same procedure.
Additionally we have demonstrated glycosylation of spectrinN
purified from normal erythrocytes (RBCN). Although the presence
of N- and O-glycosylations was found both in spectrinN and
spectrinVL, enhanced sialylation was largely induced only in
spectrinVL. Controlled tryptic fragments of a- and b-spectrinVL
exhibited the presence of terminal linkage specific sialic acids. This
enhanced sialylation is possibly related to the fragmentation of
spectrin in VL as evidenced by an additional 60 kDa fragment in
spectrinVL and totally absent in spectrinN. In summary, this is the
first report of glycosylation in eythrocytic spectrinN and its
modifications in diseased condition which possibly affects the
biology of RBCVL and may provide an explanation for their
sensitivity to hemolysis and anemia in VL patients.
Results
Eight distinct disease-associated 9-O-AcSGPs exclusively
induced on RBCVL
Disease-associated 9-O-AcSGPs were purified from RBCVL of
clinically confirmed untreated VL patients (n=30) using Achati-
nin-H-Sepharose 4B affinity matrix (Fig. 1A). Total membrane
protein (1.2060.187 mg) obtained from 2610
10 RBCVL yielded
0.43260.025 mg of purified 9-O-AcSGPs separated as eight
distinct bands on SDS-PAGE. Purification of the same from
RBCN (2610
10) of normal healthy individuals (n=30) by the same
procedure yielded undetectable amount of protein.
Identification of spectrin by mass spectrometry
Molecular identification of VL-associated proteins is a key to
their significance in the disease pathology. With this aim, peptide
mass fingerprint (PMF) analysis and sequencing of tryptic
fragments of the two high molecular weight bands of 9-O-AcSGPs
by MALDI-TOF/PSD-MS led to the identification of erythrocytic
a- and b-spectrin with sequences coverage of 33.6% and 22.7%
respectively (Fig. 1B–C). These tryptic fragments were mapped on
to the NCBI database sequences of human erythrocytic a- and b-
spectrin sequences gi: 119573202 and gi: 67782321 respectively
(shown in red color in Fig. S1).
SpectrinVL is specifically a 9-O-AcSGP present only in
RBCVL
The identification of erythrocytic spectrin by mass spectrometry
as O-acetylated sialoglycoprotein, prompted us to explore the
status of total spectrin in RBCVL (spectrinVL). Accordingly,
spectrins were separately purified by the method as described by
Ungewickell et al. [31]. The yield of spectrinVL purified from ghost
membrane (1.48960.064 mg) of RBCVL was 0.23160.017 mg.
Purified spectrin from RBCN (spectrinN) demonstrated only two
bands corresponding to a-, b-spectrin on SDS-PAGE (Fig. 2A,
lane 1). In contrast, purified spectrinVL exhibited an additional
60 kDa fragment along with a-, b-spectrin bands (Fig. 2A, lane 2).
Purified spectrinVL was further allowed to bind with Achatinin-H-
Sepharose 4B. Achatinin-H bound spectrinVL demonstrated three
similar bands (Fig. 2A, lane 3). These observations confirmed the
presence of 9-O-AcSA on a-, b-spectrin and 60 kDa band of
RBCVL, which was indicative of alteration of spectrin in VL.
Western blot analysis of purified spectrinVL separately by the
method as described by Ungewickell et al [31] also showed
reactivity with Achatinin-H reconfirming the identity of all three
bands as spectrin containing 9-O-AcSA (Fig. 2B). In contrast,
similar analysis of spectrinN demonstrated the absence of all these
three bands suggesting lack or undetectable 9-O-AcSA on RBCN.
SDS-PAGE analysis (5 and 7.5%) of spectrinN and spectrinVL
demonstrated slight variation in their electrophoretic mobility
(Fig. 2C) suggesting some changes in VL. Two dimensional gel
electrophoresis of purified spectrinVL reveals that individual spots
corresponding to a-spectrin and b-spectrin and 60 kDa band have
multiple isoelectric points (pI) (Fig. 2D) suggesting microheteroge-
neity of each spot possibly due to the differential sialylation of the
same protein resulting into different pI.
Identification of 60 kDa band of erythrocytic a-spectrin in
RBCVL
The 60 kDa band was identified as a fragment of a-spectrin (gi:
119573202) by mass-spectrometric PMF analysis (Fig. 3A) as well
as sequence determination of fragments from PSD spectra.
Representative MS/MS spectra of tryptic fragments of m/
z=1237.6 (Fig. 3B) and m/z=1709.8 (Fig. 3C) are shown. The
24 detected and annotated tryptic fragments matched the N-
terminal section of a-spectrin with sequence coverage of 18.4% for
the entire spectrin sequence and of 36.1% for the N-terminal exons
(Table 1).
Erythrocytic spectrinN and spectrinVL are glycosylated
The identification of sialic acids in spectrinVL prompted us to
explore the status of glycosylation of spectrin in RBCN. The
presence of comparable N- and O-glycosylation was demonstrated
by a shift in the respective protein bands corresponding to a- and
b-spectrin following enzymatic deglycosylation of neuraminidase
treated purified spectrinN and spectrinVL due to their reduced
molecular mass (Fig. 4A).
In parallel, neuraminidase treated 60 kDa fragment was also
exposed to N- and O-glycosidase F which evidenced a shift of the
band corresponding to a reduction of molecular weight by
,13.12 kDa and ,3.12 kDa indicating presence of both N- and
O-glycosydic bonds (Fig. 4B). The 60 kDa fragment also
demonstrated a shift of ,1.25 kDa after desialylation. Hence,
deglycosylation accounted for about ,16.24 kDa of the total mass
of 60 kDa.
The existence of both N-a n dO-glycosylation was further
confirmed by binding with Sepharose/agarose bound specific
lectins using iodinated spectrinVL and spectrinN (Fig. 4C–D). The
Induced Sialylation in Erythrocytic SpectrinVL
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125I-spectrinNwithimmobilized ConcanavalinA (ConA),
Ricinus communis agglutinin (RCA), Helix pomatia agglutinin (HPA) and
Ulex europaeus agglutinin (UEA) clearly suggested the existence of N-
glycosylation. Similarly the binding of Dolichos biflorus agglutinin
(DBA) and Jacalin reflected the presence of O-glycosylation in
125I-
spectrinN. These lectins also showed affinity towards the N-a n dO-
glycosylated sugars present in
125I-spectrinVL.
Immobilized ConA and UEA showed comparable binding with
125I-spectrinN and
125I-spectrinVL suggesting equivalent glycosyl-
ation levels having a-Man (mannose), a-Glc (glucose) and a-L-Fuc
(fucose) (Fig. 4C). However immobilized RCA, HPA, DBA and
Jacalin showed higher binding towards
125I-spectrinN as compared
to
125I-spectrinVL suggesting the presence of more terminal b-D-
Gal (galactose) (GalNAc, b-Gal), a/b-D-GalNAc, a-GalNAc and
b1-3GalNAc sugars in spectrinN than spectrinVL.
The occurrence of Man a (1–3), (1–6) and (1–2) Man, Gal b
(1–3) GalNAc and Gal b (1–4) GlcNAc (N-acetylglucosamine) in
spectrinN and spectrinVL was further demonstrated based on the
comparable binding with Galanthus nivalis agglutinin (GNA),
peanut agglutinin (PNA) and Datura stramonium agglutinin (DSA)
respectively using DIG-glycan differentiation kit (Fig. 4E–F).
Erythrocytic spectrinVL is highly sialylated
Isoelectric focusing (IEF) of spectrinVL demonstrated four distinct
bands within a pI range of 4.6–5.21 (Fig. 5A), which showed a
considerable shift of their pI to a range of 6.25–7.95 after
neuraminidase treatment indicating the presence of sialic acids.
Furthermore the homogeneous shifts of the individual bands
demonstrated the homogeneity of the proteins. In contrast shift in
pI of spectrinN before and after neuraminidase treatment was less
Figure 1. Purification of 9-O-AcSGPs and identification of spectrin. A. A representative SDS-PAGE (7.5%) profile of purified 9-O-AcSGPs from
RBCVL. Lane M shows molecular weight standards. B–C. PMF spectra of tryptic fragments of two high molecular weight 9-O-AcSGPs were identified as
a- (B) and b-spectrin (C) by MALDI-TOF MS. Each fragment is denoted by their m/z values and sequence range in human a- and b-spectrin.
doi:10.1371/journal.pone.0028169.g001
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fragment showed two distinct bands, which demonstrated a shift in
their pI after desialylation. This indicated that 60 kDa fragment
comprised of two fragments of similar mass having sialic acids. Lane
Ms h o w st h ep Im a r k e r s .
Enhanced presence of SA in spectrinVL as detected by
biochemical and glycoanalytical methods
The presence of total sialic acid was demonstrated in
spectrinVL/N using DIG-glycan detection kit (Fig. 5B–C). Spec-
trinVL showed enhanced (3-fold) sialylation as compared to
spectrinN. The variable expression of linkage-specific sialic acids
was demonstrated (Fig. 5D–E). SpectrinVL showed ,2.7–2.8 fold
enhanced binding with Sambucus nigra agglutinin (SNA) and
Maackia amurensis agglutinin (MAA) compared to spectrinN.
Sialylation were further demonstrated by binding with iodinated
spectrinVL and spectrinN with Sepharose/agarose bound Wheat
germ agglutinin (WGA), SNA and MAA. SpectrinVL showed
significantly higher binding (,2.4 fold) with all three lectins than
spectrinN (Fig. 5F). Achatinin-H also showed higher binding with
spectrinVL whereas negligible with spectrinN (Fig. 5F).
With an attempt to search for the presence of sialylated tryptic
fragments, the a- and b-subunits of spectrinVL were partially
digested with trypsin separately. This controlled digestion yielded
many fragments though we might have missed many smaller
fractions (Fig. 5G). Theses fragments were allowed to bind with
SNA and MAA agarose separately. SNA and MAA bound
fragments were analysed on SDS-PAGE. Approximately 25
fragments of a-spectrinVL showed a2,6 linked and 18 of them
had a2,3 linked terminal sialic acid. b-spectrinVL showed
comparatively less number of a2,6 and a2,3 linked terminal sialic
acids containing fragments (Fig. 5H).
Glycosidically bound sialic acids (SA) liberated from spectrinVL
when separated on a TLC (thin layer chromatography) plate
Figure 2. Purification and characterization of spectrin. A. Purification of spectrinVL and spectrinN. A representative SDS-PAGE (7.5%) profile of
SpectrinN (2.0 mg, lane 1) and spectrinVL (2.0 mg, lane 2), purified from RBCN and RBCVL as described by Ungewickell et al [31]. Purified spectrinVL was
further passed through an Achatinin-H-Sepharose 4B affinity column and 9-O-acetylated sialic acid containing spectrinVL (2.0 mg, lane 3) was purified
as described in Materials and Methods. Lane M shows molecular weight standards. B. Presence of 9-O-AcSA as detected by Western blot analysis. Equal
amounts (2 mg) of purified spectrinVL and spectrinN were transferred onto nitrocellulose membrane after SDS-PAGE (8.5%). The blots were incubated
overnight at 4uC with Achatinin-H and processed as described in Materials and Methods. C. Equal amount (2 mg) of purified spectrinVL and spectrinN
were separated both on 5 and 7.5% SDS-PAGE under similar conditions. D. Two dimensional (2D) gel electrophoresis of spectrinVL. A representative 2D
(pI range 4–7, 4–15% gradient) profile of purified spectrin (100 mg) from RBCVL after staining with Coomassie is shown.
doi:10.1371/journal.pone.0028169.g002
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and Neu5,9Ac2 (5,9-diacetyl neuraminic acid) as compared with
standard Neu5Ac and free SA purified from bovine submandib-
ular mucin (BSM) (Fig. 6A). The presence of these derivatives was
also demonstrated in the chromatogram of the liberated SA from
spectrinVL by fluorimetric high-performance liquid chromatogra-
phy (HPLC) (Fig. 6B). The Neu5,9Ac2 peak of spectrinVL
completely disappeared on saponification. In contrast, spectrinN
showed undetectable Neu5,9Ac2 suggesting disease-associated
modification. BSM-derived SA showing ,40% Neu5,9Ac2 was
used as standard. Each fraction corresponding to Neu5Ac and
Neu5,9Ac2 of spectrinVL was collected after fluorimetric-HPLC
and was subsequently confirmed by MALDI-TOF-MS which
yielded their expected molecular ion signals having m/z at 448.1
(Fig. 6C) and 490.1 (Fig. 6D) respectively.
Molecular modelling of glycosylated residues
In a-spectrin, four potential N-glycosylation sites were identified
all of which contains the consensus sequence, Asn-Xaa-Ser/Thr
(Table 2). However, only one potential O-glycosylation site was
found at Thr-817 position with a score above the threshold value
(0.35). However, in b-spectrin, two potential N-glycosylation sites
were found and no potential O-glycosylation site (Table 2).
Structural verification of the predicted models of the modules
containing N- and O- linked glycosylation sites revealed that the
backbone conformations were satisfactory as the allowed phi-psi
combinations were above 90% in the allowed region of
Ramachandran’s plot. Verify 3-D results showed that the models
have an average 85% of the residues with 3D-1D score greater
than 0.2 which indicates good quality 3D structural parameters.
From ERRAT analysis it was observed that most of the models
Figure 3. Identification of 60 kDa band. A. The PMF spectra of tryptic fragments of 60 kDa glycoprotein. PMF spectra of tryptic fragments of
60 kDa were identified as N-terminal fragment of a-spectrin by MALDI-TOF MS. Each fragment is denoted by their m/z values and sequence range
within the 955 amino acids of human a-spectrin (marked with yellow in Fig. S1). B–C. Confirmation of the sequence of the identified tryptic fragments by
MALDI-TOF-TOF mass spectrometry. The MS/MS spectrum was analyzed with database-dependent MASCOT as well as database-independent Sequit!
software systems yielding the same results. Two representative PSD spectra of the MS/MS analysis of the fragment (B) LQATYWYHR (m/z=1237.6)
and (C) HEDFEEAFTAQEEK (m/z=1237.6) of a-spectrin and SGP-60. The N and C terminal fragment ions are denoted according to standard
nomenclature and immonium ions displayed in single amino acid code.
doi:10.1371/journal.pone.0028169.g003
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structural quality.
Solvent accessible surface areas was calculated by ACCESS and
the probable glycosylation sites shows that the residues are exposed
enough needed for glycosylation at the sites (Table 2). Further,
modelling of a representative sugar (b-GlcNAc) into one each of N-
and O- glycosylation sites showed that the sugar moiety can go into
the available space around the amino acid residues (Fig. 7).
SpectrinN and spectrinVL showed slight variations in their
secondary structures
The CD (Circular Dichroism) spectra of spectrinN in far-UV
(ultra violet) region showed that protein contains 51.71% of a-
helix, 9.17% of b-sheet and 39.12% of random coil (Fig. 8A). The
similar trend was observed in the secondary structure prediction
using GOR 4 [32]. The sequences of a- and b-spectrinN was taken
as weighted averages; the values of a-helix, b-sheet and random
coil are 71.61%, 4.98% and 23.28% respectively. In parallel, the
values for a-helix, b-sheet and random coil are 77.9%, 3.03% and
18.71% respectively as predicted from the modelled structures
using MODELYN [33].
However, spectrinVL demonstrated a slight increase of a-helicity
(63.05%) and a minimal decrease of b-sheet (5.68%) structure
suggesting higher degree of sialylation possibly playing a role for
such minute changes in its secondary structure.
Binding of
125I-spectrinN and
125I-spectrinVL to
spectrin-depleted inside-out membrane vesicles (IOV)
In order to further demonstrate the modified structure of
spectrinVL in comparison to spectrinN we have compared the
binding status of iodinated spectrinVL and spectrinN with spectrin-
depleted IOV from normal RBC-ghost (IOVN). The binding of
125I-spectrinVL to spectrin-depleted IOVN increases with increas-
ing amount of
125I-spectrinVL (Fig. 8B). In contrast, under
identical condition,
125I-spectrinN showed much higher binding
towards spectrin-depleted IOVN. Such differences in binding
signifies that minute structural modifications due to enhanced
sialylation in spectrinVL possibly make it less available for
interacting with other associated proteins in the spectrin-depleted
IOVN of RBCN.
Discussion
VL is often complicated by anemia. The exclusive presence of
9-O-AcSGPs on erythrocytes of active VL has been correlated to
RBC hemolysis [18,20]. The functional attributes of erythrocytes
Table 1. The 24 tryptic fragments of 60 kDa band determined by MALDI-TOF-MS analysis.
Mass [M+H]
+ Sequence range Deviation from theoretical mass Missed cleavage Sequence
1316.8079 17–27 0.14 0 VLETAEEIQER
1378.8979 49–59 0.19 0 LEDSYHLQVFK
1534.9679 49–60 0.17 1 LEDSYHLQVFKR
1374.8279 119–130 0.21 0 FTMGHSAHEETK
1452.9379 199–210 0.17 1 KFEDFQVELVAK
1324.8279 200–210 0.15 0 FEDFQVELVAK
1216.6979 239–248 0.13 0 QNEVNAAWER
1237.7579 366–374 0.14 0 LQATYWYHR
2240.4279 390–411 0.28 0 TAAINADELPTDVAGGEVLLDR
2532.3879 426–448 0.27 0 FQSADETGQDLVNANHEASDEVR
1339.7179 484–494 0.16 0 DSEQVDSWMSR
1355.7279 484–494 0.17 0 DSEQVDSWMox.SR
2476.5179 495–517 0.29 0 QEAFLENEDLGNSLGSAEALLQK
1709.9579 518–531 0.23 0 HEDFEEAFTAQEEK
2839.5879 678–701 0.21 1 QKGTLHEANQQLQFENNAEDLQR
2583.4879 680–701 0.27 0 GTQLHEANQQLQFENNAEDLQR
2604.5279 740–762 0.28 0 QDQVDILTDLAAYFEEIGHPDSK
1377.8679 837–848 0.12 0 VILENIASHEPR
1647.9479 859–873 0.20 0 MVEEGHFAAEDVASR
1663.9579 859–873 0.22 0 Mox.VEEGHFAAEDVASR
1191.7279 876–885 0.14 0 SLNQNMESLR
2447.4879 917–939 0.29 1 EKEPIVDNTNYGADEEAAGALLK
1968.2079 940–956 0.26 1 KHEAFLLDLNSFGDSMox.K
1840.0479 941–956 0.18 0 HEAFLLDLNSFGDSMox.K
The tryptic fragments matched the N-terminal portion of human erythrocytic a spectrin as compared to the protein sequences of the NCBI sequence database. The
identification was confirmed by complete de novo sequencing of two fragments (shown in Figure 3 B–C). Mass [M+H]
+ denotes the mono-isotopic masses of the
fragment ions; sequence range refers to the alignment of the sequence of the denoted fragments with the a-spectrin reference sequence (gi: 119573202); deviation
from theoretical mass is the mass difference between the measured mass and the mass calculated from the corresponding database sequence; missed cleavage refers
to the missed trypsin cleavage sites in the identified fragment; sequence is the fragment sequence in one-letter code, Mox is oxidized methionine.
doi:10.1371/journal.pone.0028169.t001
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is often described in terms of alterations in the membrane
characteristics like osmotic fragility, fluidity and hydrophobicity.
Any kind of perturbation in the milieu of the erythrocytes like
oxidative changes or ligand specific interaction culminates in
changes in the membrane characters generally associated with
pathological conditions [25]. Therefore, we considered it worth-
while to unravel the molecular determinants and implications of 9-
O-AcSGPs on RBCVL.
The major observation of this study is the demonstration of
glycosylation in normal spectrin purified from RBCN, presence of
higher degree of sialylation in spectrin purified from RBCVL and
fragmentation of spectrinVL as a 60 kDa 9-O-AcSGP. Therefore, it
may be envisaged that enhanced sialylation of spectrinVL is
possibly responsible for the generation of this fragmented O-
acetylated sialic acid-containing spectrinVL. Altered binding of
highly sialylated spectrinVL with spectrin-depleted inside-out
membrane vesicles of RBCN possibly suggested functional
abnormality. Membrane characteristics of RBCVL were observed
by enhanced hydrophobicity, fragility, fluidity as compared to
RBCN hinting towards membrane damage [25].
We have purified eight distinct 9-O-AcSGPs from RBCVL using
Achatinin-H as an affinity matrix indicating linkage specific
terminal 9-O-AcSA in these sialoglycoproteins. Distinct multiple
spots of individual 9-O-AcSGP suggested microheterogeneity
possibly due to differential sialylation. As 9-O-AcSGPs are
Figure 4. Demonstration of N-and O-glycosylation. A. Demonstration of N-and O-glycosylation of spectrin by enzyme deglycosylation. Equal
amount (5 mg) of purified spectrinVL and spectrinN was treated with neuraminidase from Arthrobacter ureafaciens to remove the terminal sialic acids
and subsequently desialylated spectrinVL and spectrinN was incubated separately with N-glycosidase F, O-glycosidase or a combination of N- and O-
glycosidase as indicated. SpectrinVL/N before and after the respective enzyme treatments were analyzed by SDS-PAGE as described in Materials and
Methods. B. Demonstration of sialylation, N- and O-glycosylation in 60 kDa fragment. Gel-eluted purified 60 kDa fragment (1.0 mg) was initially
desialylated with Arthrobacter ureafaciens neuraminidase overnight at 37uC. Subsequently the desialylated 60 kDa fragment was treated separately
with N-glycosidase F, O-glycosidase F or a combination of both and analyzed by SDS-PAGE (7.5%) along with the untreated protein as described in
Materials and Methods. Gel was stained with silver staining method. Lane M shows molecular weight standards. C–D. Demonstration of N- and O-
glycosylation by lectin binding with
125I-spectrinVL/N. Fixed concentrations of
125I-spectrinVL/N were processed separately to demonstrate their binding
with several Sepharose/agarose bound ConA, RCA, HPA, UEA, DBA and Jacalin lectins (25 ml bead volume) having different sugar-linkage specificity as
described in Materials and Methods. E–F. Demonstration of N- and O-glycosylation by lectin binding with DIG-glycan. E. Equal amount (2.0 mg) of
spectrinVL and spectrinN was dot blotted on NC-paper and analyzed by DIG-glycan and differentiation kit using several lectins (GNA, PNA, DSA)
following manufacturer’s protocol. F. Representative bar graph of densitometric scores of corresponding spots.
doi:10.1371/journal.pone.0028169.g004
Induced Sialylation in Erythrocytic SpectrinVL
PLoS ONE | www.plosone.org 7 December 2011 | Volume 6 | Issue 12 | e28169exclusively present on RBCVL, their identification through mass
spectrometry was necessary to assess their possible implication in
the disease pathology.
The analysis of two high molecular weight 9-O-AcSGPs by
MALDI-TOF-MS evidenced a match with the NCBI entry of
human erythrocytic a and b-spectrin with sequence coverage of
33.6% and 22.7% respectively. The amino acid sequences of
tryptic fragments deduced from MS analysis confirmed the
identification. Sequencing of two tryptic fragments and data-
base-dependent Mascot as well as database-independent Sequit
analyses made the identification unambiguous.
The cytoskeleton beneath the lipid bilayer of the membrane of
RBC comprises of several proteins interconnected with each other
providing stability and integrity to the membrane structure.
Spectrin exists as a heterotetramer consisting of two subunits each
of a-(280 kDa) and b-(246 kDa) spectrin oriented in an anti-
Figure 5. Presence of Neu5Ac and Neu5,9Ac2 in spectrinVL by biochemical methods. A. Enhanced sialylation demonstrated by IEF. Equal
amounts (3.0 mg) of purified spectrinVL, 60 kDa band and spectrinN before and after removal of sialic acids were analyzed by IEF within a pH gradient
of 3–10 and the respective bands visualized by silver staining. Lane M shows the pI markers. B–C. Enhanced sialylation in spectrinVL. Equal amount
(1.0 mg) of purified spectrinVL and spectrinN was analyzed by using DIG-glycan detection kits and total sialylation was compared based on the
densitometric scores of spots (B). Representative bar graph of densitometric scores of corresponding spots (C). D–E. Detection of linkage-specific
terminal sialic acids in spectrinVL. Equal amount (2.0 mg) of spectrinVL and spectrinN was dot blotted on NC-paper and analyzed by DIG glycan and
differentiation kit using SNA and MAA lectins following manufacturer’s protocol (D). Densitometric scores of corresponding spots are shown as bar
graph (E). F. Binding of
125I-spectrinVL/N with several sialic acid binding lectins. To demonstrate the presence or absence of terminal sialic acids, a fixed
concentrations of
125I-spectrinVL/N were analyzed by binding with Sepharose/agarose bound WGA, SNA, MAA, Achatinin-H (25 ml bead volume)
having specificity towards linkage specific sialic acids as described in materials and methods. Bound radioactivity of
125I-spectrinVL/N was measured by
Gamma-counter and represented as bar graphs. G–H. Detection of sialylated tryptic fragments in spectrinVL. The a and b subunits of purified spectrinVL
were digested separately by restricted amount of trypsin. Such controlled digested and extracted tryptic fragments were dried and redissolved and
an aliquot was separated in SDS-PAGE (7.5%–15% gradient) (G). Subsequently the presence of sialic acids on resulting tryptic fragments was analyzed
by binding with SNA-agarose and MAA-agarose separately and followed by electrophoresis on SDS-PAGE (7.5%–15% gradient) (H) as described in
Materials and Methods. Lane M shows the molecular weight standerds.
doi:10.1371/journal.pone.0028169.g005
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was indicated by shifts in molecular mass after the respective
glycosidase treatments of neuraminidase-treated spectrinVL and
spectrinN. Binding with several lectins specific for N- and O-
glycosylation also supported the presence of such glycosylation in
spectrinVL and spectrinN.
Molecular modelling studies also supported both N-&O-
glycosylations of a-specrin. However, only N-glycosylation was
found in b-spectrin. Modelling the sugar moiety to the predicted
glycosylation sites suggested that glycans could fit into these sites
without any steric clashes, thus signifying the probability of
glycosylation of spectrin.
Cell surface sialic acids have been widely associated with
different pathological conditions. Enhanced presence of sialic acids
in spectrinVL has been convincingly exhibited by lectin binding,
which was further confirmed by TLC, fluorimetric-HPLC and
MALDI-TOF-MS. Demonstration of pI of spectrinVL in acidic
region and a huge shift of pI after neuraminidase treatment
Figure 6. Presence of Neu5Ac and Neu5,9Ac2 in spectrinVL by analytical methods. A. Thin layer chromatography (TLC). Glycosidically bound
sialic acids of spectrinVL were subjected to acid hydrolysis, purified, separated on a TLC plate and detected by staining with orcinol/HCl spray reagent
and baking at 180uC. Similarly processed free sialic acids released from BSM served as standard. Additionally, commercially available Neu5Ac was used
as references. For comparison liberated sialic acids from purified spectrinN were similarly analyzed. B. Enhanced presence of Neu5Ac and Neu5,9Ac2 in
spectrinVL as determined by fluorimetric HPLC. Glycosidically bound sialic acids released from spectrinVL by acid hydrolysis were derivatized with DMB
and analyzed by fluorimetric HPLC before and after saponification as described in Materials and Methods. A representative chromatogram of the
spectrinVL and spectrinN derived sialic acids showed the presence of fluorescent derivatives of free sialic acids. In parallel sialic acids of BSM similarly
analyzed under identical conditions served as standard. C–D. Identification of sialic acids by MALDI-TOF MS. Fractions corresponding to peaks of
Neu5Ac (C) and Neu5,9Ac2 (D) were collected after fluorimetric HPLC, spotted and analyzed by MALDI-TOF MS using DHBA matrix as described in
Materials and Methods. Positive ion mode was used for mass-spectrometric analysis with 1000 laser shots per spot.
doi:10.1371/journal.pone.0028169.g006
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importantly, exclusive presence of Neu5,9Ac2 in spectrinVL
suggested disease-associated enhanced sialylation in VL. En-
hanced sialylation in spectrinVL compared to spectrinN possibly
causes structural modification of spectrinVL. Such structural
changes were perhaps the basis for the reduced capacity of
spectrinVL to complex with other associated cytoskeletal proteins
in normal environment as demonstrated by its less binding with
spectrin-depleted IOVN.
Interestingly, purified 60 kDa fragment demonstrated the
presence of two distinct bands in IEF and each of the bands
depicted a distinct shift in their pI after removal of SA showing the
presence of two sialylated proteins of similar molecular mass. In
contrast spectrinN having comparable glycosylation, showed
complete absence of such fragmentation, which suggested that
alteration of spectrin mainly enhanced sialylation may be
associated with VL pathology.
The cleaved 60 kDa fragment which belongs to a-spectrin
contains two potential N-linked glycosylation sites, at Asn-633 &
Asn-657 and one O-linked glycosylation site at position Thr-817
with sufficient surface accessibility. The remaining portion of a-
spectrin although contains two potential N-linked glycosylation
sites, but no O-linked glycosylation site was found. On the other
hand, we could not identify any potential O-linked glycosylation
site in the b-spectrin. Therefore, it may be envisaged that the
exclusive presence of O-linked glycosylation site in the N-terminal
region of a-spectrin with high surface accessibility tends to have
higher sialylation for interaction with each other. All these factors
combined may play important role in the cleavage of a-spectrin to
60 kDa fragment in VL.
Production of erythrocytes requires synthesis of red cell proteins
specially cytoskeleton proteins. During terminal differentiation of
erythroid progenitor cells in culture it retains the key components
of the endoplasmic reticulum protein translocation, glycosylation,
Table 2. Potential glycosylation sites and solvent accessibility
values of spectrinN.
SpectrinN Glycosylation sites
a Accessible surface area [A ˚ 2]
a-spectrin Asn-Lys-Thr [633–635] 16.94
Asn-Val-Thr [657–659] 75.37
Asn-Thr-Ser [1625–1627] 93.70
Asn-Leu-Ser [2077–2079] 52.24
Thr-817 142.89
b-spectrin Asn-Val-Thr [194–196] 45.05
Asn-Phe-Thr [197–199] 21.97
aN-glycosylation sites (Asn) are shown as the consensus sequence of three
amino acids and O-glycosylation site (Thr) is shown as the single amino acid.
Sequence numbering is done according to the human alpha spectrin ,
erythrocytic 1, isoform CRA_b (gi: 119573202, taken from NCBI protein
sequence database).
doi:10.1371/journal.pone.0028169.t002
Figure 7. Space filling structural representation of GlcNAc in spectrinN. Sugar moiety are colored by atoms (C=green, O=red, N=blue and
H=white). The protein model is represented as conolly surface. A. N- glycosylation of a-spectrin is shown in yellow color at position Asn-1625. B. N-
glycosylation of b-spectrin is shown in yellow color at position Asn-194. C. O- glycosylation of a-spectrin is shown in blue color at position Thr-817.
doi:10.1371/journal.pone.0028169.g007
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Hsp90 for red cell glycoprotein biosynthesis [34].
Non-enzymatic glycation and oxidation of spectrin were
reported under several physiological conditions [3]. Such non-
enzymatic changes are a result of glyco-oxidation, where the
oxidative stress within, surpasses the antioxidant defense system of
the cell [35]. The associated biochemical alterations affect the
structure, aggregation and integrity of the membrane and
membrane-associated proteins. Such changes have been witnessed
in erythrocytic spectrin of subjects suffering from long-term
diabetes mellitus. Here the elevated glucose concentration
increases oxidation and advanced glycation end product formation
of structural and membrane proteins of erythrocyte [36]. The
demonstration of spectrinVL with enhanced sialylation in VL
patients raised questions regarding the basis of these modifications.
Therefore, it may be envisaged that oxidative modification of
spectrin affects membrane morphology of the erythrocytes.
Enhanced fragility, membrane fluidity and hydrophobicity of
RBCVL as compared to RBCN were demonstrated earlier [25].
Hence, the evidence of altered spectrin reported here may provide
an explanation for the known-impaired stability of erythrocytes in
VL.
The presence of elevated levels of serum sialic acids in
cardiovascular diseases and their relation to evaluated myocardial
cell damage have been documented and it has been suggested that
either the shedding or secretion of cell membrane sialic acids
determines their accumulation in serum [37,38]. Furthermore, the
importance of elevated serum sialic acids and soluble sialyltrans-
ferases in the diagnosis of Down-syndrome affected pregnancy and
oral cavity cancer has been documented [39,40]. The presence of
sialyltransferases in human serum may provide a possible way of
changes in serum proteins with terminal a2-6 sialic acid [40]. Bulai
et al. have characterized a transport system and demonstrated the
uptake of free sialic acids into human erythrocytes [41]. Therefore,
free sialic acids could be transported across the membrane into
RBC through a sialic acids transport system. Interestingly, the
presence of enhanced sialic acids in the serum of VL patients
probably hinted towards a possible mechanism of transport of
these free sialic acids under the influence of sialyltransferases.
Hence presence of sialic acids in VL serum could essentially serve
as a source for the erythrocyte sialic acids, which could use a
transport system for their entry. The uptake of sialic acids was
monitored by measuring free sialic acids and ManNAc produced
by cytosolic sialate pyruvate-lyase in human erythrocytes that
indicated the presence of a sialic acid transport system [42].
Furthermore, in VL, peripheral hematopoietic cells have increased
sialic acids [26] that could be shaded in the serum and be
transported across the erythrocyte membrane. The presence of
serum sialyltransferases in VL patients and testing this hypothesis
as well as the elucidation of the mechanisms of enhanced
sialylation of spectrin in RBCVL demands extensive studies and
will be a subject of future investigations.
Taken together the current study provides evidence for the first
time not only for glycosylation of spectrinN but also enhanced
sialylation in diseased condition i.e. spectrin in RBCVL. Addition-
ally, we have demonstrated fragmented spectrinVL which could be
triggered by such enhanced sialylation. Therefore, we hypothesize
that the higher sialylation along with exclusive presence of 9-O-
AcSA on RBCVL may in turn, cleaves spectrin, ultimately resulting
in destabilization and functional inability of the RBC. From this
entire study, we contend that these 9-O-AcSGPs trigger membrane
damage and may serve as an important factor leading to anemia-
associated with VL. Hence the study successfully dissects one of
the causal mechanisms leading to anemia, a common manifesta-
tion in VL.
Materials and Methods
Clinical samples
Blood sample of clinically confirmed active VL patients (n=30;
21 males, 9 females, median age: 30 years) based on microscopic
demonstration of Leishmania sp. amastigotes in splenic aspirates
Figure 8. Physicochemical study of structural modification of spectrinVL. A. CD-spectra. Far-UV CD spectra of spectrinVL and spectrinN in
phosphate buffer (20 mM, pH 7.0) indicating the molar residue ellipticity as a function of wavelength along with the buffer only. B. Binding of
125I-spectrin to spectrin-depleted IOVN. Various concentrations of
125I-spectrinVL/N were incubated with a constant amount of spectrin-depleted-IOVN
followed by determination of specific binding as described in Materials and Methods.
doi:10.1371/journal.pone.0028169.g008
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immediately processed for the separation of RBCVL at Indian
Institute of Chemical Biology. The diagnosis was validated by two
in-house techniques, in which the increased presence of linkage-
specific 9-O-AcSGPs was quantified by erythrocyte binding assay
[17] and anti-9-O-AcSGPs antibodies were detected by enzyme-
linked immunosorbent assay (ELISA) using BSM known to
contain a high percentage of 9-O-AcSAs, as coating antigen
[30,23]. The hematological parameters evidenced anemia in these
patients and ruled out any other blood cell disorder (Table 3).
Existence of high level of sialic acid in VL serum was observed.
Peripheral blood from normal human donors from endemic
(n=15) and non-endemic areas (n=15) was processed similarly to
obtain RBCN for the study. The Institutional Human Ethical
Committee had approved the study and samples were taken with
the consent of the donors, patients, or in case of minors from their
parents/guardians.
Purification of 9-O-AcSGPs from RBCVL
RBCVL (2610
10) after Ficoll-Hypaque (Amersham Pharmacia,
Uppsala, Sweden) gradient separation comprising of 85–90% 9-O-
AcSGP-positive cells were washed consecutively thrice with
sodium chloride (NaCl, 0.15 M). Erythrocyte ghosts were
prepared by sequential lyses of RBCVL using 5.0 mM, 2.5 mM
and 1.25 mM ice-cold phosphate buffer, pH 7.0. The ghost
membranes were solubilized in solubilizing buffer containing Tris-
HCl (0.05 M), 1% (w/v) detergent concentration (CHAPS:BOG
1:1), MgCl2 (1.0 mM), CaCl2 (1.0 mM), dithiothreitol (DTT,
0.2 mM), phenylmethyl sulfonyl fluoride (PMSF, 20 mg/L),
protease inhibitor cocktail, pH 7.2, sonicated (three pulses,
10 sec each) in ice-mixture and incubated at 4uC for 1 hr [43].
After centrifugation at 82006g, 4uC the supernatant was collected
and dialyzed against Tris-HCl (0.05 M, pH 7.2) saline (TBS)
containing 0.03 M Ca
2+ (TBS-Ca
2+), 0.01% (w/v) detergent
(CHAPS: BOG 1:1), sodium azide (0.02%). The dialyzed protein
was processed for affinity chromatography and the protein content
was quantified by Lowry method [44].
RBCVL ghost membrane protein fraction (1.85 mg) was passed
through Achatinin-H-Sepharose-4B affinity column (2.0 mg/ml)
equilibrated with TBS-Ca
2+ containing sodium azide (0.02%) at
4uC as described elsewhere [18]. After extensive washing,
Achatinin-H-bound 9-O-AcSGPs were eluted at 25uC with TBS
containing sodium citrate (0.04 M, pH 7.2), dialyzed against TBS
at 4uC and stored at 270uC for future use. As the binding of
Achatinin-H towards 7-O- and/or 8-O-AcSA cannot be ruled out,
therefore, presence of such linkages in O-acetylated sialoglycopro-
teins are also possible.
Protein/peptide mass spectrometry
The identification of the glycoprotein was done by mass
spectrometry using Bruker-Daltonics MALDI-TOF mass spec-
trometer Reflex IV (Bruker Daltonics, Bremen, Germany). The
samples were prepared by dried-droplet procedure using 2,5-
dihydroxybenzoic acid (DHBA) as matrix. Calibration was done
externally with a mixture of Angiotensin I, Angiotensin II,
Substance P, Bombesine, ACTH clip 1–17 and ACTH clip 18–
39. Subsequently, peptide samples were used for analysis. Tryptic
fragments were generated by overnight in-gel digestion of two high
molecular bands in ammonium hydrocarbonate (5 mM) using
10 ng trypsin (Promega, Mannheim, Germany) per sample.
Sequence analysis of selected tryptic fragments was done with an
Ultraflex III MALDI-TOF-TOF mass spectrometer (Bruker
Daltonics). PSD spectra were acquired using default LIFT method
for MS/MS spectra acquisition with manually adjusted laser
energy accumulating data from 1500–2000 laser shots. Spectra
annotation was done using the FlexAnalysis 3.0 (Bruker Daltonics)
software. PMF analyses and MS/MS ion searches were done with
MASCOT (Matrix Science Ltd., London, UK). Database searches
through Mascot with PMF and MS/MS data were done with the
BioTools 3.1 software (Bruker Daltonics). For database searches
the following parameters were used. Taxonomy: Homo sapiens;
database: NCBI; enzyme: trypsin; variable modifications: oxida-
tion on methionine and one missed cleavages. Database searches
for PMF spectra were done at the fragment mass tolerance
60.3 Da. For the MS/MS searches mass tolerances for precursor
was 60.2 Da and 0.4 Da for fragment masses were used. The
identification of the fragments and thereby of the protein was
confirmed by database-independent de novo sequencing using the
Sequit! Software [45].
Purification of spectrin
The spectrinN from RBCN (1.25 mg total ghost membrane
protein) was purified following the method of Ungewickell et al.
with slight modifications [31]. Briefly, the ghosts were washed
twice and resuspended in 3 volume of sodium phosphate (0.3 mM,
pH 7.2) containing ethylene diamine tetraacetic acid (EDTA;
0.2 mM), (extraction buffer) and incubated for 20 min at 37uC.
The fragmented ghosts were pelleted by centrifugation at 800006
g for 1 h at 2uC. Water-soluble proteins in the supernatant were
immediately applied to a Sepharose 4B column (9062 cm),
equilibrated with Tris (25 mM), EDTA (5 mM), NaCl (0.1 M),
pH 7.6 (Tris/EDTA/saline buffer) at 4uC. The column was eluted
at 10 ml/h and 4-ml fractions were collected. Protein in the
effluent was monitored by absorbance at 280 nm. Fractions
containing purified spectrin dimer were pooled, concentrated and
dialyzed overnight at 4uC against TBS-Ca
2+ buffer containing
sodium azide. In parallel, spectrinVL was similarly purified from
Table 3. Diagnostic features of patients with active visceral
leishmaniasis (VL).
Parameters PatientVL (n=30) Normal (n=30)
Age (yr) 20–40 20–40
Weight (Kg) 32–40 50–60
Duration of illness (mo) 4–6 Not applicable
RBC count 1.0–2.5610
6/ml 4.0–6610
6/ml
Leukocyte count (/mm
3) 3–4610
3 5–10610
3
Hemoglobin concn. (g/dl) 4–5 10–12
Reticulocyte count (%) 4–5 1–3
Spleen size (cm) 7–10 Not palpable
Splenic aspirate score
a 3.5–4.2 Negative
RBC-ELISA 0.95–1.38 0.19–0.24
9-O-AcSGP
+RBC
b 85–90% 0.08–0.12%
BSM-ELISA
c 0.85–1.2 0.19–0.24
Parasite ELISA
d 1.1–1.8 0.21–0.28
Serum sialic acid content (mg/dL)
e 77.0563.6 57.4263.49
a4, .1 to 10 parasites per field.
bDetermined by flow cytometry using FITC-Achatinin-H [18].
cAnti-9-O-AcSGP antibody was detected by using BSM as coating antigen as
described elsewhere [30].
dParasite specific antibody was detected by using parasite lysate as coating
antigen as described elsewhere [16].
eSialic acid content in serum was estimated by thiobarbituric acid method [54].
doi:10.1371/journal.pone.0028169.t003
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passed through an Achatinin-H-Sepharose 4B affinity column and
9-O-AcSA containing spectrinVL was purified as described above.
Electrophoresis
2D Gel electrophoresis. Purified spectrinVL was processed
with 2D-clean up kit according to manufacturer’s protocol (Bio-
Rad, USA). The precipitated protein was dissolved in rehydration
buffer containing urea (6 M), thiourea (2 M), CHAPS (2%), DTT
(50 mM), carrier ampholyte cocktail (2%), EDTA (0.1 mM),
bromophenol blue and quantitated by Quick Strat Bradford.
Protein (100 mg/100 ml) was rehydrated on IEF strips (pI 4–7,
7 cm) for 8 hrs and ran in PROTEAN IEF cell. Strips were
equilibrated consecutively in two steps of 30 min each in
equilibration buffer containing urea (6 M), SDS (2%), Tris-HCl
(0.375 M, pH 8.8), glycerol (20%), DTT (2%) followed by same
buffer with iodoacetamide (2.5%). The second dimension was
carried out on gradient (4–15%) SDS-PAGE and stained by
Biosafe Coomassie brilliant blue [46].
Purified spectrinN, spectrinVL or affinity-purified spectrinVL and
gel eluted 60 kDa fragment and were analysed by SDS-PAGE (5
and 7.5%) in a minigel apparatus (Bio-Rad, USA) [25] and the
gels were stained. N-o rO-linked glycosylation of spectrinVL,
spectrinN and 60 kDa fragment was demonstrated after deglyco-
sylation with specific glycosidases using deglycosylation kit (Roche
Applied Science, Mannheim, Germany) according to the manu-
facturer’s protocol [26].
Western blot analysis [26] of spectrinVL and spectrinN was
performed by semidry method at 15 V for 20 min. After blocking,
the membranes were incubated with Achatinin-H (100 mg/ml) in
the presence of Ca
2+ (0.03 M). Subsequently, the Achatinin-H
probed membrane was incubated with polyclonal rabbit anti-
Achatinin-H antibodies (1:400) at 4uC. Both the blots were
developed using HRP-conjugated goat anti-rabbit IgG (1:5000,
Cell signaling) and detected using diaminobenzidine (Sigma, St.
Louis, MO) as substrate.
To obtain pure 60 kDa protein, Coomassie-stained bands
corresponding to 60 kDa were excised from the electrophoresis
gels and the proteins eluted using an Electro-Eluter Model 422
(Bio Rad, USA). IEF of purified spectrinVL, gel-eluted 60 kDa
fragment and spectrinN was performed in capillary tubes within a
pH range 3.0–10.0 using Mini-PROTEAN II tube cell apparatus
(Bio-Rad, USA) and silver stained. The samples were desialylated
overnight with Arthrobacter ureafaciens neuraminidase (0.2 mU/mg)
at 37uC and processed similarly. The isoelectric points were
determined from the pI of known proteins used as standards [26].
Analysis of carbohydrates
DIG-glycan detection. Equal amounts (1.0 mg) of spectrinVL
and spectrinN were dot blotted on nitrocellulose paper (NC-paper)
and total sialic acid content was analyzed by using DIG-glycan
detection kit (Roche Applied Science, Mannheim, Germany)
following manufacturer’s protocol [8]. Densitometric
measurement of spots was done by using ImageQuantTL
software (GE Healthcare).
DIG-glycan differentiation. The detection of terminal
sugars on equal amount (2.0 mg, dot blotted on NC-paper) of
spectrinVL and spectrinN was analyzed [26] by DIG-Glycan
differentiation kit (Roche Applied Science, Mannheim, Germany)
using several plant lectins SNA (specific for a2R6 linked Neu5Ac),
MAA (specific for a2R3 linked Neu5Ac), GNA (specific for
terminal Man (a1R3), (a1R6) and (a1R2) Man), PNA (specific
for Gal (b1R3) GalNAc) and DSA (specific for Gal (b1R4)
GlcNAc) according to the manufacturer’s protocol. Densitometric
measurement of spots was done as above.
Immobilizedlectinbindingassaysto
125I-spectrinVL/N. To
analyze the terminal sugar linkages, spectrinVL and spectrinN were
separately iodinated with
125I (Bhabha Atomic Research Centre,
Mumbai,India) yielding specific activity of spectrinN 1.96610
6 cpm/
mga n do fs p e c t r i n VL 1.8610
6 cpm/mg respectively. Fixed
concentrations of
125I-spectrinVL/N were incubated separately with
Sepharose/agarose bound lectins (25 ml bead volume) of different
sugar-linkage specificity. Con A (specific for a-Man and a-Glc), RCA
(specific for b-D-Gal (GalNAc, b-Gal)), HPA (specific for a-or b-D-
GalNAc), UEA (specific for a-L-Fuc) were used to demonstrate the
presence of N-glycosylation. Similarly Jacalin (specific for
b1,3GalNAc) and DBA (specific for a-GalNAc) were used to
illustrate the presence of O-glycosylation. The lectins WGA (specific
forGlcNAcandNeu5Ac),SNA,MAA,Achatinin-H(specificfor9-O-
acetyl sialoglycosyl residue) were used to show the presence of sialic
acids. Unbound radioactivity was removed using TBS-bovine serum
albumin (1 mg/ml) and bound
125I-spectrinVL/N was measured by
Gamma-counter (Electronic Corporation, India) [47].
Identification of sialoglycopeptides from spectrinVL
containing a2,6 and a2,3 linked sialic acids. Purified
spectrinVL (150 mg) was run in 5% SDS-PAGE and a-spectrin &
b-spectrin bands were digested partially by trypsin (200 ng) using
in-gel trypsin digestion kit (Pierce, Rochford, USA) following the
manufacturer’s protocol. Digested and extracted tryptic fragments
were dried under speed-vac and redissolved in 0.1% TFA (100 ml).
An aliquot of the redissolved tryptic fragments were seperated on
7.5%–15% gradient SDS-gel. Remaining portion was neutralized
by Tris-HCl (pH 8.0) and an aliquot was incubated separately
with SNA-agarose (10 ml) and MAA-agarose (10 ml) for overnight
at 4uC under mild shaking. The mixture was centrifuged at
5000 rpm for 10 min, supernatant collected as unbound fraction.
Pellet was suspended in cold phosphate buffered saline (0.02 M,
pH 7.0) and centrifuged at 5000 rpm for 10 min. Washed pellet
was boiled with SDS-PAGE sample buffer, centrifuged at
5000 rpm for 5 min and the supernatant was ran in 7.5%–15%
gradient gel.
TLC. Glycosidically bound sialic acids were released from
purified spectrinVL (60 mg) by hydrolysis with propionic acid
(4 M) for 4 h at 80uC. Liberated SA was subsequently passed
onto Dowex 50WX8 (100–200 mesh) cation and Dowex 268
(200–400 mesh) anion exchange columns. Free sialic acids eluted
from these columns were separated on TLC plates (Merck
KGaA, Germany) in 1-propanol/H2O (7:3 v/v) and developed
by spraying with orcinol/HCl/FeCl3 with heating at 180uCf o r
20 min [8,26]. Commercially available sialic acids (Neu5Ac,
Sigma) along with those released from BSM served as standards.
In parallel, sialic acids released from spectrinN were similarly
processed.
Fluorimetric HPLC. An aliquot of liberated sialic acids was
derivatized with 1,2-diamino-4,5-methylenedioxybenzene (DMB)
and DMB-SA was separated on an RP-18 column (LichroCART
125-4 HPLC-cartridge, 5 mm; Merck, Germany) and detected at
excitation and emission wavelengths of 373 nm and 448 nm
respectively as described elsewhere [8,26 48]. In parallel, sialic
acids purified from BSM were run for comparison.
MALDI-TOF MS. Each fraction corresponding to different
forms of sialic acids was collected from fluorimetric HPLC and
subsequently analyzed by MALDI-TOF-MS (Applied Biosystem,
USA) using DHBA as matrix as described previously [8,26,48].
Positive ion mode was used for analysis. The acquired spectra were
accumulations of 1000 laser shots.
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Prediction of glycosylation sites. The protein sequences of
human erythrocytic a-&b-spectrin were collected from NCBI
database (gi: 119573202 and gi: 67782321 respectively). Prediction
of N-glycosylation sites were performed with NetNGlyc 1.0 server
(http://www.cbs.dtu.dk/services/NetNGlyc/). Predictions of O-
glycosylation sites were done with NetOGlyc 3.1 server (http://
www.cbs.dtu.dk/services/NetOGlyc/) [49]. Probable glycosylation
sites above a threshold value of 0.35 were selected for solvent
accessibility calculation.
3-D structural modelling of spectrin modules. 3D
structure of the modules containing the potential glycosylation
sites were modelled using Swiss Model software [50]. The quality
of the models was validated using Structural Analysis and
Verification Server (http://nihserver.mbi.ucla.edu/SAVES/).
Solvent accessibility of probable glycosylation sites. Sol-
ventaccessibilitysurfaceareaofallaminoacidsresiduesofthemodels
were calculated using ACCESS software [51]. The probable N-a n d
O- linked glycosylation sites were identified by their percentage of
surface exposure. Sites falling within the identified segments of a-a n d
b-spectrin sequences by MASCOT program with significantly high
intensity were eliminated from the list of probable sites as their non-
glycosylated status was confirmed.
Attachment of carbohydrates to probable glycosylation
sites. The structures of the modules attached to the
carbohydrate at assigned Asn and Thr of the identified N-&O-
glycosylation sites were optimized using molecular modelling
software suite InsightII (2005) of Accelrys (San Diego, CA) by
repeated energy minimization and molecular dynamics
simulations with DISCOVER module. Energy minimization was
performed alternatively with steepest descent and conjugate
gradient methods (200 steps each using cff91 force field).
Molecular dynamics simulation run was done with 10,000 steps
of 1 fs after 1000 steps of equilibration with a conformation
sampling of one in 100 steps at 300 K. At the end of the molecular
dynamics simulation, the lowest potential energy conformation
was picked using ANALYSIS module of Insight II for further
energy minimization. The molecular dynamics simulation
followed by energy minimization was performed on the
glycosylation site residues attached with the sugar moiety while
keeping the rest of the protein molecule fixed by applying
positional constraints. This process was continued until satisfactory
conformational parameters were achieved [26].
Physicochemical studies
CD spectra of spectrin. Far-UV CD spectra (between
190 nm and 250 nm) measurement of equal amount (0.05 mg/ml)
of spectrinVL and spectrinN were performed at 25uC on a JASCO J-
715 spectropolarimeter using a quartz cuvette of path length 1 mm
under continuous flush of nitrogen gas. The spectra shown are the
average of ten data collected in continuous scan mode. The
individual secondary structural contents of a-helix, b-sheet, and
random coil were analyzed from the far-UV CD spectra using the
K2D2 software [52].
Preparation of spectrin-depleted inside-out vesicles
(IOVs) and binding with
125I-spectrinVL/N. Ghosts from
RBCN were incubated for 30 min at 37uC in 30 vol of EDTA
(0.25 mM), PMSF (25 mg/ml), pH 8.0, centrifuged at 50,000 g for
25 min and the inside-out vesicles (IOVs) were suspended in the
buffer containing sodium phosphate (10 mM), KCl (130 mM),
NaCl (20 mM), EDTA (1 mM), NaN3 (0.5 mM), DTT (1 mM),
pH 7.5 (Buffer A). Spectrin-depleted-IOVN was stored at a
concentration of 1 mg/ml for overnight at 4uC [53].
To demonstrate the binding of spectrinN with spectrin-depleted-
IOVN,
125I-spectrinN (0–10 mg/ml) were incubated for 90 min at
0uC in a buffer A (100 ml) containing 20 mg/ml spectrin-depleted-
IOVN protein [53] and centrifuged at 50,000 g for 25 min at 4uC.
Membrane-bound
125I-spectrin was washed with Buffer A and the
radioactivity was counted by a Gamma-counter (Electronic
Corporation, India). Nonspecific binding at each
125I-spectrinN
concentration was determined by the use of heat-denatured (70uC,
15 min) spectrin, and this value (10–28% of total counts) was
routinely subtracted [53].
Estimation of sialic acid (SA) in serum. Estimation of total
SA in serum was carried out colorimetrically by the thiobarbituric
acid method after hydrolysis with 0.1 N sulfuric acid at 80uC for
1 hr [54]. The absolute value of sialic acid in serum was obtained
from standard curve of authentic Neu5Ac.
Results are expressed as means 6 S.D for individual sets of data.
Each experiment was performed at least 3 times.
Supporting Information
Figure S1 Sequence of a-spectrin and b-spectrin with
the identified and annotated fragments in red and the
sequenced fragments underlined.
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